menu
    • menu
    [{"orgOrder":0,"company":"HDT Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"HDT-301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"HDT Biotech \/ Not Applicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"National Institute of Allergy and Infectious Diseases.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"HDT-301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HDT Biotech","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ National Institute of Allergy and Infectious Diseases.","highestDevelopmentStatusID":"4","companyTruncated":"HDT Biotech \/ National Institute of Allergy and Infectious Diseases."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Zoic Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"HDT-301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Zoic Capital","highestDevelopmentStatusID":"4","companyTruncated":"HDT Biotech \/ Zoic Capital"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Gennova Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"HGCO19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HDT Biotech \/ HDT Biotech Corporation","highestDevelopmentStatusID":"7","companyTruncated":"HDT Biotech \/ HDT Biotech Corporation"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HDT Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Not Applicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Gennova Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HDT Biotech \/ Gennova Biopharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Gennova Biopharmaceuticals"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Quratis Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HDT Biotech \/ Quratis Inc","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Quratis Inc"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Gennova Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ HDT Bio Corp","highestDevelopmentStatusID":"7","companyTruncated":"HDT Biotech \/ HDT Bio Corp"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Quratis Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Quratis","highestDevelopmentStatusID":"6","companyTruncated":"HDT Biotech \/ Quratis"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Not Applicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HDT Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Not Applicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"HDT-521","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HDT Biotech \/ BARDA","highestDevelopmentStatusID":"5","companyTruncated":"HDT Biotech \/ BARDA"}]

    Find Clinical Drug Pipeline Developments & Deals by HDT Biotech

    Menu

    HDT Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HDT-521

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : BARDA

                            Deal Size : $0.7 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            HDT Bio Receives $7.9M EZBAA Contract and Partners with BARDA for NextGen Enabler Program

                            Details : The partnership aims to support HDT in advancing its next-generation vaccine HDT-521. Which is being evaluated in the preclinical trial studies for the treatment of prostate cancer.

                            Brand Name : HDT-521

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : HDT-521

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : BARDA

                            Deal Size : $0.7 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HDT Bio’s COVID-19 Vaccine Wins Regulatory Approval in India

                            Details : The vaccine uses self-amplifying RNA (or “saRNA”), which replicates itself following administration and is thus effective at extremely low doses. In addition, it is stable at refrigerator temperatures—unlike current mRNA vaccines.

                            Brand Name : HDT-301

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 29, 2022

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HDT Bio Demonstrates RNA Vaccines Matched to SARS-CoV2 Variants Protect Against Infection of Upper Airways, Im...

                            Details : HDT301, an HDT Bio’s technology uses self-replicating RNA and has the potential to deliver a COVID-19 vaccine targeting multiple variants, providing broad protection from disease and reduced transmission from breakthrough infections.

                            Brand Name : HDT-301

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 05, 2022

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HGCO19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Quratis Co., Ltd

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HDT Bio Partner Quratis Doses First Healthy Volunteers in Phase 1 Trial of HDT Bio’s RNA COVID-19 Vaccine in...

                            Details : Company RNA-based vaccine, HDT-301 (HGCO19) offers simpler manufacturing, greater stability, and vastly lower effective dosing than current mRNA COVID-19 vaccines.

                            Brand Name : HDT-301

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 13, 2021

                            Lead Product(s) : HGCO19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Quratis Co., Ltd

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HGCO19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Gennova Biopharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India

                            Details : Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials.

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            August 31, 2021

                            Lead Product(s) : HGCO19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Gennova Biopharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Quratis Co., Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            HDT Bio Announces Agreement With Korea’s Quratis to Co-Develop Innovative COVID-19 Vaccine in Asia

                            Details : This agreement will enable Quratis to manufacture HDT Bio's next-generation COVID-19 vaccine, HGCO19 and distribute it across much of East Asia.

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 16, 2021

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Quratis Co., Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Gennova Biopharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HDT Bio Receives Notice to Proceed from FDA for U.S. Phase 1 Clinical Trial of RNA COVID-19 Vaccine

                            Details : HDT Bio has also developed HGCO19, a LION-based COVID-19 vaccine, in collaboration with Gennova Biopharmaceuticals of Pune, which is currently is being tested in India in a Phase 1/2 clinical trial.

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            July 01, 2021

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Gennova Biopharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HDT Bio, Gennova Biopharmaceuticals Announce First Healthy Volunteers Dosed in Phase I/II Trials Of Unique COV...

                            Details : HGCO19, is a novel mRNA vaccine candidate containing a short, synthetic version encoding the spike protein (antigen) of the novel coronavirus, SARS-CoV-2, reported to interact with receptors on host cells.

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            May 04, 2021

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HGCO19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Gennova Biopharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gennova Biopharmaceuticals Granted Conditional Permission for Human Clinical Trial of Its Covid-19 Vaccine

                            Details : The Drugs Controller General of India (DCGI) has granted conditional permission for phases 1 and 2 human clinical trial of the COVID-19 vaccine candidate, HGCO19, developed by the Pune-based Gennova Biopharmaceuticals Ltd in collaboration with HDT, USA.

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 09, 2020

                            Lead Product(s) : HGCO19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Gennova Biopharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            HDT Biotech

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Zoic Capital

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            HDT Bio Announces Completion of Seed Financing Round

                            Details : Proceeds will be used largely to support continued development of the company’s COVID-19 vaccine candidate, HDT-301. The vaccine is slated to enter clinical trials in Q4 2020 in partnership with the NIH/NIAID.

                            Brand Name : HDT-301

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 05, 2020

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Zoic Capital

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth